CG0070 Plus Nivolumab Under Investigation in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
May 4th 2022The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.
Read More
Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC
May 4th 2022Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.
Read More
Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer
May 3rd 2022Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.
Read More
Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer
May 1st 2022Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.
Read More
The European Commission has granted an approval to the combination of pembrolizumab and chemotherapy, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher.
Read More
Frontline Tislelizumab/Chemo Combo Improves OS in Advanced Esophageal Squamous Cell Carcinoma
April 27th 2022The combination of tislelizumab and chemotherapy resulted in a significant improvement in overall survival compared with chemotherapy alone in patients with locally advanced, recurrent or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 expression.
Read More
Novel Agents Continue to Drive Treatment of NSCLC With EGFR, MET, and ALK Abnormalities
April 27th 2022Jun Zhang, MD, PhD, discusses key clinical trials utilizing immunotherapy in non–small cell lung cancer, the continued importance of biomarker testing to help inform treatment decisions, and targeted therapies for EGFR, MET, and ALK mutations.
Read More
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab alone after surgery for adult patients with locally advanced or early-stage triple-negative breast cancer who are at a high risk for recurrence.
Read More
CAR T-cell Therapy Demonstrates Efficacy Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
April 25th 2022The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.
Read More
FDA Grants Fast Track Designation to CMG901 in Relapsed/Refractory Metastatic Gastric/GEJ Cancer
April 21st 2022The FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric and gastroesophageal junction cancer that is relapsed or refractory to approved therapies.
Read More
Pembrolizumab/Lenvatinib Plus Chemo May Represent “Powerful” Option for NSCLC
April 20th 2022Roy S. Herbst, MD, PhD, discusses the rationale for exploring immunotherapy/TKI combinations like pembrolizumab plus lenvatinib in patients with non–small cell lung cancer, and outlined the different efforts that comprise the LEAP clinical trial program.
Read More
HER2-Targeted CAR Macrophage CT-0508 Under Exploration in Solid Tumors with HER2 Overexpression
April 19th 2022The safety, tolerability, and preliminary efficacy of the anti-HER2 CAR macrophage therapy, CT-0508, will be investigated in patients with solid tumors and HER2 overexpression, as part of a first-in-human phase 1 study.
Read More
Second Line T-DM1 Worsens Outcomes for HER2+ Breast Cancer in Real-World Study
April 19th 2022Trastuzumab emtansine as a second-line treatment led to shorter median treatment duration and time to treatment failure in patients with HER2-positive metastatic breast cancer who progressed on pertuzumab and trastuzumab–based regimens.
Read More
Bortezomib Improves OS in Newly Diagnosed T-Cell Lymphoblastic Leukemia and Lymphoma
April 18th 2022The addition of bortezomib to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma, according to data from the phase 3 AALL1231 trial.
Read More
Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLL
April 14th 2022A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.
Read More
BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma
April 12th 2022The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.
Read More
Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL
April 12th 2022The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.
Read More
Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC
April 1st 2022The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.
Read More
Patritumab Deruxtecan Shows Early Potential in Second-Line EGFR Inhibitor–Resistant, EGFR+ NSCLC
March 31st 2022The newer generation antibody-drug conjugate patritumab deruxtecan has elicited encouraging responses with acceptable safety in patients with EGFR TKI–resistant, EGFR-mutated non–small cell lung cancer—a difficult-to-treat population with an unmet medical need.
Read More
NDA Resubmitted to FDA for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors
March 24th 2022A new drug application for a unique formulation of sodium thiosulfate was resubmitted to the FDA for the second time for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have localized, nonmetastatic, solid tumors.
Read More
Olaparib Shows Comparable OS to Chemotherapy in BRCA+, Platinum-Sensitive, Relapsed Ovarian Cancer
March 19th 2022Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.
Read More